FEATURE ARTICLES

The Secrets To CSL Limited’s Incredible Revenue Growth
The Secrets To CSL Limited’s Incredible Revenue Growth

CSL Limited’s CEO Paul Perreault gives us a behind-the-scenes look at how the company increased revenue by 33% while also increasing R&D by 73% and capital investment by 83%.

More featured articles

ALSO IN THIS MONTH'S ISSUE

  • What JPM 2017 Revealed To Me
    What JPM 2017 Revealed To Me

    As I walked into a breakout session on at JPM, I couldn’t help but overhear people discussing the latest negative news to hit the biopharma industry.

  • Trump Targets The Pharmaceutical Industry
    Trump Targets The Pharmaceutical Industry

    Our new President seemed to criticize recent inversions, but more importantly vowed to go after the industry: “Our drug industry has been disastrous.

  • Getting An Accurate Count Of Counterfeit Drugs
    Getting An Accurate Count Of Counterfeit Drugs

    The first of a four-part, in-depth series on the ongoing problem of counterfeit medicines. In this article, we talk about how the Counterfeit Incidence System (CIS) is better tracking the number of law enforcement cases involving pharmaceutical crimes.

  • What Gets Funded, What Dies Before It Gets To Pharma R&D
    What Gets Funded, What Dies Before It Gets To Pharma R&D

    Lots of people in our industry are wondering how to simultaneously bring value to patients and the organization. It’s a reasonable aspiration, but is it possible?

  • Most U.S. Pharmas Ignore Cuba, Despite Relaxed Rules
    Most U.S. Pharmas Ignore Cuba, Despite Relaxed Rules

    Two American organizations go on the record to discuss their work with Cuban researchers and their efforts to bring innovative research involving cancer vaccines and levels of consciousness (e.g., comas, brain death) to American patients.

More from Life Science Leader

WEB-EXCLUSIVE EDITORIAL

  • Alternative Fact: Site Identification Is Not Critical To Clinical Trial Efficiency
    Alternative Fact: Site Identification Is Not Critical To Clinical Trial Efficiency

    On the surface this may seem to have some validity, as sponsors and CROs often lack a transparent, evidence-based strategy for this task. Instead, they frequently rely on archaic paper-based or spreadsheet methods to identify sites across the globe with a reasonable chance of enrolling the contracted number of patients on schedule, and the ability to generate quality data.

  • Survey Says: Pharma Perspectives On Implementation & Impact Of Recent Regulatory Guidances
    Survey Says: Pharma Perspectives On Implementation & Impact Of Recent Regulatory Guidances

    Over the past 10 years, both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued new and revised regulations and guidances in an attempt to define, clarify, and modernize their requirements. Ideally, these documents would have aided industry in developing new products that take advantage of new technologies, given budget and personnel limitations in both the regulatory agencies and industry. And in fact, many of these documents have proposed or emphasized radical changes in strategy and operations, but unfortunately such changes are often met with skepticism and concern by industry.

  • Novartis And The Arrival Of The Continuous Manufacturing Facility
    Novartis And The Arrival Of The Continuous Manufacturing Facility

    The journey to implementation of the disruptive technology of continuous manufacturing began in 2005, according to Markus Krumme of Novartis, with a single question on a slide presented to Novartis development and manufacturing executives. “Why don’t we have facilities that can continuously produce materials?” then-CEO Daniel Vasella asked.

  • Launching A New Drug In A Maturing Market — Lessons Learned From Recent COPD Entrants
    Launching A New Drug In A Maturing Market — Lessons Learned From Recent COPD Entrants

    Chronic obstructive pulmonary disease (COPD), a global growth market worth well over $15 billion in the U.S. and EU5 in 2016, has long represented a lucrative opportunity for drug manufacturers. However, the proliferation of treatments and increasing number of generics have begun to limit the potential for emerging therapies. A review of the successes and stumbles of the newest class of drugs (LABA/LAMA fixed-dose combinations) illustrates broader lessons manufacturers should consider when launching into a rapidly maturing market.

  • Drug Pricing: 2017’s Challenge Confronting Biopharma
    Drug Pricing: 2017’s Challenge Confronting Biopharma

    Although just a part of total healthcare costs, drug prices have certainly attracted a lot of comments from politicians and mentions in the press. If the issue was limited to being primarily a talking point exploited by politicians to generate populist support, it might be one thing; however, the politicians’ commentary is giving voice to a more significant concern among the public.

More web-exclusive editorial

CUTTING ROOM FLOOR EDITORIAL

  • CSL Limited CEO Shares Insights Beyond Just How To Grow Revenue

    Being the head of any Big Pharma is bound to test an executive’s work-life balance. But when that Big Pharma is headquartered in Australia, and the company prides itself on being a “global operation,” maintaining any kind of work-life balance is a formidable task. “I’m not the poster child for how to strive for work-life balance,” admits Paul Perreault, CEO and managing director of CSL.

  • 9 Questions With Takeda Oncology’s Chief Counsel And Head Of Patient Advocacy

    In 2002 Liz Lewis joined Takeda where she is currently chief counsel and head of patient advocacy at Takeda Oncology. Lewis sat down with me to share how she helped enhance Takeda Oncology’s patient advocacy organization.

  • What Will The Global Biopharmaceutical Industry Look Like In 2027: Trendsetter Series Part 4 of 4

    The executive-level participation for Life Science Leader magazine's signature 2017 Outlook issue had an overwhelming. This year’s feature article involved 13 executive life science leaders! In part four of this series, which is a supplement to the feature magazine article, we pose the question, “Looking even further ahead, what is your vision for how the global biopharmaceutical industry might look in the year 2027?”

More cutting room floor editorial

LIFE SCIENCE TRAINING INSTITUTE COURSES

CRO Oversight: Risk Assessment & Action Planning March 1, 2017
1pm-2:30pm EST, Online Training
Bioprocess Facility Design - Layout Rules and Configurations March 8, 2017
1pm-2:30pm EST, Online Training
Data Integrity - Detecting & Mitigating Risk March 14, 2017
1pm-2:30pm EST, Online Training
More training courses

FEBRUARY 2017 DIGITAL EDITION

BLOGS

More blogs

@LIFESCILEADER1

2016 CRO AWARDS SPECIAL EDITION

2016 CMO AWARDS SPECIAL EDITION

 UPCOMING EVENTS

Laboratory Data Integrity: Current Expectations for OOS Result Investigations February 24, 2017
1pm-2:30pm EST, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
The New Medical Device Reporting (MDR) Guidance – An Easily Digestible Compliance Breakdown February 27, 2017
1pm-2:30pm EST, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
7th Edition Medical Affairs Leaders Forum Europe (Spring) February 28, 2017 - March 2, 2017
Zürich
CRO Oversight: Risk Assessment & Action Planning March 1, 2017
1pm-2:30pm EST, Online Training
Price:  $299 - Includes Bonus Handouts!
Ruby Williams March 2 - 3, 2017
Amsterdam, NM
More events